612 related articles for article (PubMed ID: 18800291)
1. Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats.
Abou-Donia MB; El-Masry EM; Abdel-Rahman AA; McLendon RE; Schiffman SS
J Toxicol Environ Health A; 2008; 71(21):1415-29. PubMed ID: 18800291
[TBL] [Abstract][Full Text] [Related]
2. Expert panel report on a study of Splenda in male rats.
Brusick D; Borzelleca JF; Gallo M; Williams G; Kille J; Wallace Hayes A; Xavier Pi-Sunyer F; Williams C; Burks W
Regul Toxicol Pharmacol; 2009 Oct; 55(1):6-12. PubMed ID: 19567260
[TBL] [Abstract][Full Text] [Related]
3. Sucralose, a synthetic organochlorine sweetener: overview of biological issues.
Schiffman SS; Rother KI
J Toxicol Environ Health B Crit Rev; 2013; 16(7):399-451. PubMed ID: 24219506
[TBL] [Abstract][Full Text] [Related]
4. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
5. The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis.
Rodriguez-Palacios A; Harding A; Menghini P; Himmelman C; Retuerto M; Nickerson KP; Lam M; Croniger CM; McLean MH; Durum SK; Pizarro TT; Ghannoum MA; Ilic S; McDonald C; Cominelli F
Inflamm Bowel Dis; 2018 Apr; 24(5):1005-1020. PubMed ID: 29554272
[TBL] [Abstract][Full Text] [Related]
6. Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450.
Zhu S; Huang R; Hong M; Jiang Y; Hu Z; Liu C; Pei Y
Eur J Pharm Sci; 2009 Jul; 37(5):573-80. PubMed ID: 19442720
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Metabolism and Bioaccumulation of Sucralose In Adipose Tissue In The Rat.
Bornemann V; Werness SC; Buslinger L; Schiffman SS
J Toxicol Environ Health A; 2018; 81(18):913-923. PubMed ID: 30130461
[TBL] [Abstract][Full Text] [Related]
8. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
9. Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats.
Li C; Kim CS; Yang JY; Park YJ; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(4):231-6. PubMed ID: 19230596
[TBL] [Abstract][Full Text] [Related]
10. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
11. The artificial sweetener Splenda intake promotes changes in expression of c-Fos and NeuN in hypothalamus and hippocampus of rats.
de-la-Cruz M; Millán-Aldaco D; Soriano-Nava DM; Drucker-Colín R; Murillo-Rodríguez E
Brain Res; 2018 Dec; 1700():181-189. PubMed ID: 30201258
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
Lee CK; Ki SH; Choi JS
Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of Splenda, Equal and sucrose: Clues from planarians on sweeteners.
Ouyang K; Nayak S; Lee Y; Kim E; Wu M; Tallarida CS; Rawls SM
Neurosci Lett; 2017 Jan; 636():213-217. PubMed ID: 27845240
[TBL] [Abstract][Full Text] [Related]
15. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
16. Sucralose revisited: rebuttal of two papers about Splenda safety.
Schiffman SS; Abou-Donia MB
Regul Toxicol Pharmacol; 2012 Aug; 63(3):505-8; author reply 509-13. PubMed ID: 22579627
[No Abstract] [Full Text] [Related]
17. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
18. Fructose-induced metabolic syndrome decreases protein expression and activity of intestinal P-glycoprotein.
Novak A; Godoy YC; Martinez SA; Ghanem CI; Celuch SM
Nutrition; 2015 Jun; 31(6):871-6. PubMed ID: 25933496
[TBL] [Abstract][Full Text] [Related]
19. Intestinal P-glycoprotein inhibitors, benzoxanthone analogues.
Chae SW; Lee J; Park JH; Kwon Y; Na Y; Lee HJ
J Pharm Pharmacol; 2018 Feb; 70(2):234-241. PubMed ID: 29238994
[TBL] [Abstract][Full Text] [Related]
20. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
